This study will independently assess the efficacy and safety of three combination therapies for the treatment of patients with relapsed/refractory multiple myeloma (RR MM): selinexor + dexamethasone + pomalidomide (SdP) and selinexor + dexamethasone + bortezomib (SdB), selinexor + dexamtheasone + lenalidomide.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
SPd (Arm 1) Only:
Relapsed and refractory MM with:
SVd (Arm 2) Only:
Relapsed or refractory MM with
SRd in RRMM (Arm 3) Only:
Patients who received ≥ 1 prior therapeutic regimen (prior lenalidomide is allowed as long as patient's MM was not refractory to prior lenalidomide; patients whose MM was refractory to lenalidomide maintenance regimens will be allowed in this cohort).
SPVd (Arm 4) Only:
Patients whose MM is relapsing after ≥ 1 prior therapy with progression on their last therapy.
SDd (Arm 5) Only:
SKd (Arm 6) Only:
Patients may have received prior bortezomib or carfilzomib therapy, however their MM must NOT be refractory to carfilzomib.
SRd in NDMM (Arm 7) Only:
Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:
The following is a listing of trial locations that are open and accepting patients.
This trial has active trial locations in countries outside of the United States.
Our system currently only provides clinical trial matching services for myeloma patients in the United States.
You can view this clinical trial's international locations by visiting ClinicalTrials.gov. Please note the information provided through the government website may be inaccurate and/or out-dated.
There are no resources, links or videos to display for this clinical trial.